Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation. (9th July 2021)
- Record Type:
- Journal Article
- Title:
- Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation. (9th July 2021)
- Main Title:
- Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation
- Authors:
- Guillon, Antoine
Pardessus, Jeoffrey
L'Hostis, Guillaume
Fevre, Cindy
Barc, Celine
Dalloneau, Emilie
Jouan, Youenn
Bodier‐Montagutelli, Elsa
Perez, Yonatan
Thorey, Camille
Mereghetti, Laurent
Cabrera, Maria
Riou, Mickaël
Vecellio, Laurent
Le Guellec, Sandrine
Heuzé‐Vourc'h, Nathalie - Abstract:
- Abstract : Background and Purpose 255: Pseudomonas aeruginosa is a main cause of ventilator‐associated pneumonia (VAP) with drug‐resistant bacteria. Bacteriophage therapy has experienced resurgence to compensate for the limited development of novel antibiotics. However, phage therapy is limited to a compassionate use so far, resulting from lack of adequate studies in relevant pharmacological models. We used a pig model of pneumonia caused by P. aeruginosa that recapitulates essential features of human disease to study the antimicrobial efficacy of nebulized‐phage therapy. Experimental Approach: (i) Lysis kinetic assays were performed to evaluate in vitro phage antibacterial efficacy against P. aeruginosa and select relevant combinations of lytic phages. (ii) The efficacy of the phage combinations was investigated in vivo (murine model of P. aeruginosa lung infection). (iii) We determined the optimal conditions to ensure efficient phage delivery by aerosol during mechanical ventilation. (iv) Lung antimicrobial efficacy of inhaled‐phage therapy was evaluated in pigs, which were anaesthetized, mechanically ventilated and infected with P. aeruginosa . Key Results: By selecting an active phage cocktail and optimizing aerosol delivery conditions, we were able to deliver high phage concentrations in the lungs, which resulted in a rapid and marked reduction in P. aeruginosa density (1.5‐log reduction, p < .001). No infective phage was detected in the sera and urines throughout theAbstract : Background and Purpose 255: Pseudomonas aeruginosa is a main cause of ventilator‐associated pneumonia (VAP) with drug‐resistant bacteria. Bacteriophage therapy has experienced resurgence to compensate for the limited development of novel antibiotics. However, phage therapy is limited to a compassionate use so far, resulting from lack of adequate studies in relevant pharmacological models. We used a pig model of pneumonia caused by P. aeruginosa that recapitulates essential features of human disease to study the antimicrobial efficacy of nebulized‐phage therapy. Experimental Approach: (i) Lysis kinetic assays were performed to evaluate in vitro phage antibacterial efficacy against P. aeruginosa and select relevant combinations of lytic phages. (ii) The efficacy of the phage combinations was investigated in vivo (murine model of P. aeruginosa lung infection). (iii) We determined the optimal conditions to ensure efficient phage delivery by aerosol during mechanical ventilation. (iv) Lung antimicrobial efficacy of inhaled‐phage therapy was evaluated in pigs, which were anaesthetized, mechanically ventilated and infected with P. aeruginosa . Key Results: By selecting an active phage cocktail and optimizing aerosol delivery conditions, we were able to deliver high phage concentrations in the lungs, which resulted in a rapid and marked reduction in P. aeruginosa density (1.5‐log reduction, p < .001). No infective phage was detected in the sera and urines throughout the experiment. Conclusion and Implications: Our findings demonstrated (i) the feasibility of delivering large amounts of active phages by nebulization during mechanical ventilation and (ii) rapid control of in situ infection by inhaled bacteriophage in an experimental model of P. aeruginosa pneumonia with high translational value. … (more)
- Is Part Of:
- British journal of pharmacology. Volume 178:Number 18(2021)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 178:Number 18(2021)
- Issue Display:
- Volume 178, Issue 18 (2021)
- Year:
- 2021
- Volume:
- 178
- Issue:
- 18
- Issue Sort Value:
- 2021-0178-0018-0000
- Page Start:
- 3829
- Page End:
- 3842
- Publication Date:
- 2021-07-09
- Subjects:
- bacteriophage -- inhalation -- pneumonia -- pseudomonas aeruginosa -- ventilation‐associated pneumonia
Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.15526 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26943.xml